RxSight prices public offering of 4M shares at $12.50 each for ~$50M gross proceeds

RxSight, Inc.

Offering of 4,000,000 shares of common stock at $12.50 per share; gross proceeds ~$50.0M, net ~$46.7M.
Underwriters granted 30-day option to purchase up to 600,000 additional shares at same price.
Offering expected to close February 10, 2023; BofA Securities sole bookrunning manager.
Net proceeds to fund commercial expansion, product development, R&D, and working capital.
Officers and directors subject to 90-day lock-up restrictions on share sales.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

RxSight, Inc. entered into Underwriting Agreement with BofA Securities, Inc., as representative of the several underwriters valued at approximately $46.7 million (effective 2023-02-07).

Action: entry
Agreement: underwriting
Counterparty: BofA Securities, Inc., as representative of the several underwriters
Value: approximately $46.7 million
Effective: 2023-02-07

Exact text from the filing

On February 7, 2023, RxSight, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative (the “Representative”) of the several underwriters listed in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell 4,000,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”).

View on SEC.gov

Browse all material agreements →

RxSight, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-027742

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.